Matinas BioPharma Announces a Research Evaluation with Top Global Pharma Company Based on Its Proprietary Drug Delivery Platf...
January 10 2019 - 8:00AM
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical
stage biopharmaceutical company, today announced they have signed
an agreement with an undisclosed top global pharmaceutical company
aimed to evaluate synergistic effects of Matinas’
lipid-nano-crystal (“LNC”) platform delivery technology with their
partner’s nucleic acid polymer technology. Formulations will be
developed using Matinas’ LNC delivery technology which enables the
development of a wide range of difficult-to-deliver molecules.
Promising formulations will be tested in in vitro and in vivo
preclinical studies. For competitive reasons, the agreement
stipulates certain confidential provisions, including the
pharmaceutical company’s identity, the therapeutic molecule(s), the
intended targets and the financial terms of the agreement.
“We are delighted to announce this research
agreement with a global pharmaceutical company,” said Jerome D.
Jabbour, CEO of Matinas BioPharma. “We believe our LNC technology
platform has the potential to become an important delivery solution
for a variety of treatment paradigms where inefficient or
ineffective delivery mechanisms are currently tolerated because of
the lack of an ideal alternative. This evaluation, focused on
oligonucleotides, represents an important first step in our
strategy of exploring how our LNC delivery technology can provide
solutions for companies developing innovative nucleic acid
polymers, small molecule drugs, vaccines, proteins and potentially
even gene-editing technologies. We are thrilled to have been
selected by a leading healthcare company to potentially help
identify solutions to challenges related to drug delivery.”
Matinas’ LNC delivery platform has far greater
flexibility than other lipid nanoparticle approaches and offers an
intracellular drug delivery solution with potential advantages for
a range of therapeutics. It has demonstrated preclinically the
ability to formulate and thereby re-design a wide variety of
molecules and drugs which, (i) require delivery technology to
improve the stability of molecules inside and outside of the body,
(ii) could benefit from efficient delivery and cellular uptake by
target cells, and (iii) are currently only available in IV
formulations or (iv) otherwise experience significant
toxicity-related adverse events.
About Matinas BioPharma Matinas
BioPharma is a clinical-stage biopharmaceutical company focused on
(i) the development of MAT9001 for abnormalities in blood lipids,
referred to as dyslipidemia, and the treatment of cardiovascular
and metabolic disease, and (ii) enabling the delivery of
life-changing medicines using our unique and proprietary, lipid
nano-crystal (“LNC”) platform technology, including development of
MAT2203, our lead antifungal platform drug candidate.
The Company's proprietary, disruptive technology
utilizes lipid-crystal nano-particle cochleates to nano-encapsulate
small molecules, nucleic acid polymers, vaccines and other
medicines potentially making them safer, more tolerable, less toxic
and orally bioavailable. The Company's lead anti-fungal product
candidate, MAT2203, positions Matinas BioPharma to become a leader
in the safe and effective delivery of anti-infective therapies
utilizing its proprietary LNC formulation technology.
In addition, the Company is actively pursuing
the development of MAT9001 with the support of a world-class team
of clinical key opinion leaders and regulatory consultants. MAT9001
is a prescription-only omega-3 fatty acid-based composition,
comprised primarily of EPA and DPA, under development for
hypertriglyceridemia, which has shown superiority versus Vascepa®
(icosapent ethyl) in reducing serum triglycerides, Total- and
Non-HDL-Cholesterol, apolipoproteins and PCSK9 levels.
For more information, please visit
www.matinasbiopharma.com and connect with the Company on Twitter,
LinkedIn and Facebook.
Matinas Forward Looking
Statements: This release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including those relating to the Company's
strategic focus and the future development of its product
candidates, the anticipated timing of regulatory submissions, the
anticipated timing of clinical studies, the anticipated timing of
regulatory interactions, the Company’s ability to identify and
pursue development and partnership opportunities for its products
or platform delivery technology on favorable terms, if at all, and
the ability to obtain required regulatory approval and other
statements that are predictive in nature, that depend upon or refer
to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to obtain additional capital to meet our liquidity needs on
acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials of our product
candidates; our ability to successfully complete research and
further development and commercialization of our product
candidates, including MAT2203 and MAT9001; the uncertainties
inherent in clinical testing; the timing, cost and uncertainty of
obtaining regulatory approvals; our ability to maintain and derive
benefit from the Qualified Infectious Disease Product (QIDP),
Orphan and/or Fast Track designations for MAT2203, which does not
change the standards for regulatory approval or guarantee
regulatory approval on an expedited basis, or at all; our ability
to protect the Company's intellectual property; the loss of any
executive officers or key personnel or consultants; competition;
changes in the regulatory landscape or the imposition of
regulations that affect the Company's products; and the other
factors listed under "Risk Factors" in our filings with the SEC,
including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this release. Except as may be
required by law, the Company does not undertake any obligation to
release publicly any revisions to such forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. Matinas BioPharma's
product candidates are all in a development stage and are not
available for sale or use.
Investor ContactJenene ThomasJenene Thomas
Communications, LLCPhone: +1 (833) 475-8247Email:
mtnb@jtcir.com |
Media
ContactEliza Schleifstein Scient Public RelationsPhone: +
1 (917) 763-8106 Email: eliza@scientpr.com |
Source: Matinas BioPharma Holdings, Inc.
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Apr 2023 to Apr 2024